These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16264875)

  • 1. Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
    Lenz G; Dreyling M
    Nat Clin Pract Oncol; 2005 Feb; 2(2):72-3. PubMed ID: 16264875
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen.
    Magni M; Di Nicola M; Carlo-Stella C; Matteucci P; Devizzi L; Tarella C; Benedetti F; Martelli M; Patti C; Parvis G; Rambaldi A; Barbui T; Gianni AM
    Bone Marrow Transplant; 2009 Mar; 43(6):509-11. PubMed ID: 18955979
    [No Abstract]   [Full Text] [Related]  

  • 3. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.
    Bauwens D; Maerevoet M; Michaux L; Théate I; Hagemeijer A; Stul M; Danse E; Costantini S; Vannuffel P; Straetmans N; Vekemans MC; Deneys V; Ferrant A; Van Den Neste E
    Br J Haematol; 2005 Nov; 131(3):338-40. PubMed ID: 16225653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
    Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
    van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
    Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
    Orciuolo E; Buda G; Pelosini M; Petrini M
    Br J Haematol; 2010 Mar; 148(5):810-2. PubMed ID: 19919649
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
    Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
    Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.
    de Guibert S; Jaccard A; Bernard M; Turlure P; Bordessoule D; Lamy T
    Haematologica; 2006 Mar; 91(3):425-6. PubMed ID: 16531272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Maintenance therapy with rituximab].
    Krankenpfl J; 2005; 43(7-10):222-4. PubMed ID: 16515293
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
    Evens AM; Winter JN; Hou N; Nelson BP; Rademaker A; Patton D; Singhal S; Frankfurt O; Tallman MS; Rosen ST; Mehta J; Gordon LI
    Br J Haematol; 2008 Feb; 140(4):385-93. PubMed ID: 18162124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma.
    Lim SH; Esler WV; Periman PO; Beggs D; Zhang Y; Townsend M
    Br J Haematol; 2008 Jul; 142(3):482-4. PubMed ID: 18510683
    [No Abstract]   [Full Text] [Related]  

  • 14. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response.
    Crysandt M; Neumann B; Das M; Engelbertz V; Bendel M; Galm O; Osieka R; Jost E
    Eur J Haematol; 2007 Dec; 79(6):546-9. PubMed ID: 17903214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
    Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
    Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
    J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
    Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
    Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
    Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.